Just Released: "Non-Hodgkin's Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017"

New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
Spread the Word
Listed Under



Massachusetts - US

Nov. 14, 2010 - PRLog -- GlobalData, the industry analysis specialist has released a new report, "Non-Hodgkin's Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global NHL market. The report identifies the key trends shaping and driving the global NHL market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NHL sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

GlobalData estimated the global Non-Hodgkin's Lymphoma (NHL) market to be worth $6.5 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 7.74% annually over the next eight years to reach $11.9 billion by 2017. This growth can be primarily attributed to increased competition among the existing products, the release of new and enhanced treatment options, and the development of safer and more efficacious therapies. The NHL market growth will be further supported by the increased uptake of chemotherapy regimens, monoclonal antibodies and biologics. In 2009, Genentech Inc. (Roche), with its key drug Rituxan, was the leading player in the global NHL market. In 2009, Rituxan played a key role accounting to more than 80% share in the global NHL market. Pharmaceuticals and biopharmaceutical companies are under the way in reorganizing their NHL pipeline with combination therapies. There are six approved drugs in 2008, and two new drugs were approved by FDA in the first quarter of 2009. NHL pipeline is strong with 264 drugs under different stages of clinical development. Drugs that are studied with Rituxan either belong to the new mechanism of action or to the existing/old mechanism of action. Combination therapies in clinical studies projected to be more efficacious and safer than monotherapies alone. In future, the NHL market is driven by combination therapies, monoclonal antibodies, biologics, and vaccines. GlobalData analyzed that the global NHL market is moderately served with current product options with significant scope available to new entrants that would capture value from underserved segments.  

GlobalData analyzes that the global NHL market would double its revenues by 2017. In 2009, Genentech, Inc. accounted to be the NHL market leader with a share of more than 80%, which was contributed by its key drug Rituxan. Forthcoming monotherapies and combination therapies would much more satisfy NHL patients with safer drug profiles. The competitive landscape is populated by eight major products, of which two drugs were launched in the first half of 2009.  All these drugs were moderately successful in increasing the survival rate of patients with NHL. However, companies like GlaxoSmithKline plc. (GSK), Biogen Idec, Genzyme Corporation, Genitope Corporation, Hana Biosciences, Cell Therapeutics, Inc., Millennium Pharmaceuticals, Inc. and Novartis AG, Pfizer Inc. / Wyeth having some of the most technologically advanced products in their pipeline, are expected to attract most of the investors attention. The global NHL market is expected to see intense competition in the future.


The report analyzes market opportunities and challenges for the global NHL market. Its scope includes  

* Annualized global NHL market revenues data from 2001 to 2009, forecast forward for eight years to 2017.
* Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
* Pipeline analysis data provides a split across different phases, mechanism of actions being developed and emerging trends. Key classes of mechanism of action include CD targetors, anti-CD20 monoclonal antibodies, antineoplastic agents, histone deacetylase inhibitors, B-cell lymphoma 2 inhibitors, CD22 antigens, anti-angiogenesis inhibitors, DNA synthesis inhibitors, syk kinase inhibitors and proteasome inhibitors.
* Analysis of the current and future market competition in the global NHL market. Key market players covered are Genentech Inc., GSK, Biogen Idec, Genzyme Corporation, Cell Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Pfizer Inc. / Wyeth, and Genitope Corporation.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NHL

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

* Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
* Develop business strategies by understanding the trends shaping and driving the global NHL market.
* Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NHL market in future.
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
* Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
* Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
* What's the next big thing in the global NHL market landscape? - Identify, understand and capitalize.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/92070_nonhodgkins_lymphoma_nhl...

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.  View more research from GlobalData at http://www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:***@fastmr.com Email Verified
Tags:Pipeline, Lymphoma, Non-hodgkin, Nhl, Clinical, Drug, Therapeutic, Oncology, Globaldata, Inhibitors
Industry:Medical, Research, Biotech
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share